Literature DB >> 22186909

Trends in radiation exposure from clinical nuclear medicine procedures in Shanghai, China.

Yanling Yi1, Junzheng Zheng, Weihai Zhuo, Linfeng Gao.   

Abstract

OBJECTIVES: This study was designed to assess the trends in the frequencies of nuclear medicine procedures in Shanghai, China, and to determine their contributions to the per capita effective dose to the Shanghai population. The mean activities of radionuclides administered by nuclear medicine departments were compared with the Chinese national guidelines on diagnostic reference levels.
METHODS: On the basis of the three surveys carried out by Shanghai Municipal Center for Disease Control and Prevention in 1996, 1998, and 2008, the typically administered radiopharmaceuticals, levels of activity, the number of procedures, and population were systematically analyzed to assess the frequencies of nuclear medicine procedures and the per capita effective dose.
RESULTS: The frequencies were approximately 2.77, 3.46, and 6.63 per 1000 people in 1996, 1998, and 2008, respectively. The annual per capita doses from diagnostic nuclear medicine were estimated to be 0.016, 0.022, and 0.032 mSv in 1996, 1998, and 2008, respectively. The annual frequency of therapeutic nuclear medicine procedures increased from 0.131 to 0.430 per 1000 people in the intervening 12 years.
CONCLUSION: In the 12 years before 2008, diagnostic and therapeutic procedures in nuclear medicine in Shanghai increased continuously, and the annual per capita dose doubled. Increases in PET imaging and bone scans were the major contributors to the increasing frequency and magnitude of radiation exposure to the population. The activities administered for most diagnostic procedures were generally consistent with the designated reference levels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22186909     DOI: 10.1097/MNM.0b013e32834f2a28

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

1.  Changing incidence and projections of thyroid cancer in mainland China, 1983-2032: evidence from Cancer Incidence in Five Continents.

Authors:  Mandi Li; Jiao Pei; Minghan Xu; Ting Shu; Chengjie Qin; Meijing Hu; Yawei Zhang; Min Jiang; Cairong Zhu
Journal:  Cancer Causes Control       Date:  2021-06-21       Impact factor: 2.506

2.  Time trends and age-period-cohort analyses on incidence rates of thyroid cancer in Shanghai and Hong Kong.

Authors:  Shao-Hua Xie; Juan Chen; Bo Zhang; Feng Wang; Shan-Shan Li; Chang-Hui Xie; Lap-Ah Tse; Jin-Quan Cheng
Journal:  BMC Cancer       Date:  2014-12-18       Impact factor: 4.430

3.  Estimation of the occupational exposure dose for medical diagnostic X-ray workers in Jiangsu, China, using a retrospective dosimetry method.

Authors:  Xiao-San Xu; Lian-An Zhang; Quan-Fu Sun; Yong-Chun Qin; Ning-Le Yu
Journal:  J Radiat Res       Date:  2018-03-01       Impact factor: 2.724

4.  Trend dynamics of thyroid cancer incidence among China and the U.S. adult population from 1990 to 2017: a joinpoint and age-period-cohort analysis.

Authors:  Yiran Cui; Sumaira Mubarik; Ruijia Li; Chuanhua Yu
Journal:  BMC Public Health       Date:  2021-03-31       Impact factor: 3.295

5.  Transcriptomic profiling reveals gene expression in human peripheral blood after exposure to low-dose ionizing radiation.

Authors:  Fang Fang; Xiaoling Yu; Xiaochun Wang; Xiaojun Zhu; Lantao Liu; Li Rong; Dongsheng Niu; Jue Li
Journal:  J Radiat Res       Date:  2022-01-20       Impact factor: 2.724

6.  The epidemic of thyroid cancer in China: Current trends and future prediction.

Authors:  Jiayuan Wu; Xiaoyan Zhao; Jianzhong Sun; Chong Cheng; Chunyu Yin; Ruhai Bai
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

7.  An update on radiation absorbed dose to patients from diagnostic nuclear medicine procedures in Tehran: A study on four academic centers.

Authors:  Motahareh Motazedian; F Tabeie; P Vatankhah; B Shafiei; M Amoui; M Atefi; M Ansari; I Neshandar Asli
Journal:  Indian J Nucl Med       Date:  2016 Apr-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.